Scholarlink

Background <p>Prospective data on stereotactic body radiation therapy (SBRT) combined with modified 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) in patients with locally advanced unresectable pancreatic adenocarcinoma (PDAC) are limited.</p> Patients and Methods <p>The SABER trial was an open-label, randomized, phase 2 study. Patients with locally advanced, unresectable PDAC were eligible if they were suitable for SBRT with adherence to organ-at-risk constraints. Participants were randomized (1:1) to receive mFOLFIRINOX with or without SBRT. SBRT (35 Gy in five fractions) was administered within the first four cycles of mFOLFIRINOX. The primary endpoint was 1-year progression-free survival (PFS) rate.</p> Results <p>Between September 2021 and January 2024, 37 out of a planned 92 patients were enrolled (18 in the mFOLFIRINOX+SBRT group; 19 in the mFOLFIRINOX group); the study was terminated early due to slow accrual. SBRT was delivered to 17 (94.4%) of 18 patients. After a median follow-up of 33.3 months (90% confidence interval [CI], 28.7–40.3), median PFS was 14.0 months with mFOLFIRINOX + SBRT and 11.7 months with mFOLFIRINOX alone (hazard ratio [HR] 0.66; 90% CI 0.35–1.25; <i>p</i> = 0.281); 1-year PFS was 66.7% versus 45.1%, respectively. Median OS was 28.9 versus 28.1 months (HR 0.80; 90% CI 0.38–1.68; <i>p</i> = 0.619), respectively. The rates of 1-year cumulative local and distant progression were 11.1% versus 39.1% (<i>p</i> = 0.096) and 22.2% versus 27.4% (<i>p</i> = 0.596), respectively. Safety profiles were comparable.</p> Conclusions <p>Additional SBRT to mFOLFIRINOX was feasible without safety concerns. Although it did not improve median PFS or OS, it led to numerically improved 1-year PFS rates and local tumor control. Given premature trial closure and limited power, efficacy comparisons should be interpreted as hypothesis generating.</p> <p><i>Trial Registration</i>: NCT04986930.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 Trial

  • 期刊论文

  • 发表日期：

    2026年5月7日

查看全文
  • Changhoon Yoo,
  • Hyehyun Jeong,
  • Inkeun Park,
  • Jaekyung Cheon,
  • Baek-Yeol Ryoo,
  • Kyu-pyo Kim,
  • Dae Wook Hwang,
  • Ki-Byung Song,
  • Woohyung Lee,
  • Song Cheol Kim,
  • Tae Jun Song,
  • Dongwook Oh,
  • Ji Sung Lee,
  • Sang Soo Lee,
  • Jin-hong Park

摘要

Background

Prospective data on stereotactic body radiation therapy (SBRT) combined with modified 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) in patients with locally advanced unresectable pancreatic adenocarcinoma (PDAC) are limited.

Patients and Methods

The SABER trial was an open-label, randomized, phase 2 study. Patients with locally advanced, unresectable PDAC were eligible if they were suitable for SBRT with adherence to organ-at-risk constraints. Participants were randomized (1:1) to receive mFOLFIRINOX with or without SBRT. SBRT (35 Gy in five fractions) was administered within the first four cycles of mFOLFIRINOX. The primary endpoint was 1-year progression-free survival (PFS) rate.

Results

Between September 2021 and January 2024, 37 out of a planned 92 patients were enrolled (18 in the mFOLFIRINOX+SBRT group; 19 in the mFOLFIRINOX group); the study was terminated early due to slow accrual. SBRT was delivered to 17 (94.4%) of 18 patients. After a median follow-up of 33.3 months (90% confidence interval [CI], 28.7–40.3), median PFS was 14.0 months with mFOLFIRINOX + SBRT and 11.7 months with mFOLFIRINOX alone (hazard ratio [HR] 0.66; 90% CI 0.35–1.25; p = 0.281); 1-year PFS was 66.7% versus 45.1%, respectively. Median OS was 28.9 versus 28.1 months (HR 0.80; 90% CI 0.38–1.68; p = 0.619), respectively. The rates of 1-year cumulative local and distant progression were 11.1% versus 39.1% (p = 0.096) and 22.2% versus 27.4% (p = 0.596), respectively. Safety profiles were comparable.

Conclusions

Additional SBRT to mFOLFIRINOX was feasible without safety concerns. Although it did not improve median PFS or OS, it led to numerically improved 1-year PFS rates and local tumor control. Given premature trial closure and limited power, efficacy comparisons should be interpreted as hypothesis generating.

Trial Registration: NCT04986930.